Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A Q4 FY2024 earnings call

Management Statement and Operational Highlights

• 2024 Performance: Bruker finished 2024 with excellent CER revenue growth and solid organic growth. Delivered double-digit CER revenue growth at 14% and 4% organic growth, adding strategic acquisitions in spatial biology, molecular diagnostics, and lab automation to transform into a growth-oriented industry leader.
• 2025 Outlook: Entered 2025 with good bookings momentum, BSI segment backlog over 6 months, first orders from China stimulus, acknowledged U.S. NIH uncertainty but expects no significant reduction, with strong market trends in diagnostics and semicon metrology and biopharma recovery signs.
• Financials: Q4 2024 reported revenues $979.6M (+14.6% YOY), CER growth 15.8%, non-GAAP operating margin 18.1%. Full year 2024 revenues $3.37B (+13.6% YOY), 4% organic growth, acquisitions contributed 10%.

Segment Performance

• BioSpin Group: 2024 revenue was $905.7 million, with low teens constant exchange rate (CER) growth. Saw strong growth in Europe, Americas, industrial research, ACA/GOV markets, and biopharma, with contributions from automation, service, and software.
• CALID Group: 2024 revenue was $1.1 billion, with mid-teens CER growth. Strong growth in microbiology and infection diagnostics from MALDI Biotyper and ELITech Molecular Diagnostics acquisition, partially offset by softness in ACA/GOV and China.
• Bruker NANO: 2024 revenue was $1.1 billion, with high teens CER growth. Driven by ACA/GOV research and semiconductor metrology, with AI and HPC as tailwinds; integration of cellular analysis and spatial biology progressing but moderated by biopharma softness.
• BEST Segment: 2024 revenues grew in low single-digits, driven by accelerator and FUSION technologies at RI business, partially offset by softness in clinical MRI superconductors.

Guidance

• 2025 constant exchange rate revenue growth 5%-7%, with 3%-4% organic growth and 2%-3% from M&A.
• Non-GAAP operating profit margin expected to improve ~140 bps. Non-GAAP EPS growth 11%-13%, with CER EPS growth 14%-16%.
• Q1 2025 organic revenue roughly flat, CER mid-single digits, softer operating margin due to NanoString acquisition dilution.

Risks

• Geopolitical risks, including recent acquisitions, market demand/supply chains.
• U.S. NIH and academic government market uncertainty.
• China stimulus execution risks.
• Potential tariffs on manufacturing operations.

Q: On guidance, confidence in instrumentation sales despite NIH, A: Frank Laukien discusses various growth drivers offsetting NIH uncertainty, including biopharma recovery, China stimulus, microbiology, semiconductor, and applied markets.

Q: Biopharma recovery timing, A: Frank Laukien says gradual, expecting first half improvement, stronger in second half.

Q: TimsTOF platform and geographic backlog, A: Frank Laukien talks about expected 3 UHF NMRs, backlog composition consistent with geographic mix.

Q: China stimulus impact, A: Gerald Herman says stimulus orders spread out, baked into guidance conservatively.